
Brain Cancer Patients Demand Public Inquiry into Queen Elizabeth Hospital Birmingham Chemotherapy Errors
Brain cancer patients who received underdosed chemotherapy at Queen Elizabeth Hospital Birmingham are demanding a public inquiry into the scandal. The call follows an independent review which confirmed that many patients with glioblastoma were given insufficient doses of the drug temozolomide between 2017 and 2022.
The review, commissioned by University Hospitals Birmingham NHS Foundation Trust, identified serious concerns regarding treatment protocols. It found that patients undergoing concurrent chemoradiotherapy received a five-day cycle of temozolomide every two weeks, rather than the standard once-daily dose for 42 days. Subsequent adjuvant treatment also deviated from national guidelines.
Professor Tom Crosby, who led the independent investigation, concluded that the underdosing was substantial, potentially impacting patient outcomes. His report recommends that the trust engages with the government to discuss a broader review encompassing all patients affected by these systemic failures.
Campaigners highlight the trust's initial dismissal of concerns from clinicians as a critical failure point. This entrenched denial persisted for five years, preventing timely rectification of the errors. The patients affected, and their families, seek full accountability and a thorough, public examination of how such fundamental treatment mismanagement was allowed to occur and persist for so long within an NHS institution.






